ArticleJournal of diabetes investigation2019
Decreased placental and muscular expression of the fibroblast growth factor 19 in gestational diabetes mellitus.
Article in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Gestational diabetes as an inter-generational cardiometabolic risk factor: spotlight on emerging exerkines.Cardiovascular diabetology · 2026Review
- Integrative multi-omics analysis reveals cellular and molecular insights into gestational diabetes mellitus.Frontiers in molecular biosciences · 2026Article
- Role of FGF-19, FGF-21 and FGF-23 in Fetal and Neonatal Growth.Journal of clinical medicine · 2025Review
- Diagnosis of pregnancy disorder in the first-trimester patient plasma with Raman spectroscopy and protein analysis.Bioengineering & translational medicine · 2024Article
- The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review.International journal of molecular sciences · 2023Review
- Adiponectin, A-FABP and FGF-19 Levels in Women with Early Diagnosed Gestational Diabetes.Journal of clinical medicine · 2022Article
- FGF4, A New Potential Regulator in Gestational Diabetes Mellitus.Frontiers in pharmacology · 2022Article
- Tissue-specific mechanisms of bile acid homeostasis and activation of FXR-FGF19 signaling in preterm and term neonatal pigs.American journal of physiology. Gastrointestinal and liver physiology · 2022Article
- Fibroblast Growth Factor 19 in Gestational Diabetes Mellitus and Fetal Growth.Frontiers in endocrinology · 2021Article
- Association of Elevated Plasma FGF21 and Activated FGF21 Signaling in Visceral White Adipose Tissue and Improved Insulin Sensitivity in Gestational Diabetes Mellitus Subtype: A Case-Control Study.Frontiers in endocrinology · 2021Article
- FGF19 subfamily members: FGF19 and FGF21.Journal of physiology and biochemistry · 2019Review
- Decreased placental and muscular expression of the fibroblast growth factor 19 in gestational diabetes mellitus.Journal of diabetes investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
AIMS/
introductionFibroblast growth factor (FGF)19 has been shown to improve glycemic homeostasis and lipid metabolism in animal models. In humans, decreased FGF19 level has been described in diabetes. The present study aimed to investigate the expression of FGF19 in gestational diabetes mellitus (GDM) patients. MATERIALS AND
methodsSamples for measurement were obtained from 20 women with GDM and 25 healthy controls. The messenger ribonucleic acid (mRNA) and protein expression levels of FGF19, FGF21 and co-receptor β-klotho (KLB) in the placenta, rectus muscle and subcutaneous fat tissues were quantified by real-time quantitative polymerase chain reaction, western blot and immunohistochemistry, respectively.
resultsWomen with GDM had significantly lower mRNA and protein expressions of FGF19 than control women in the placenta (mRNA 0.33 ± 0.05 vs 0.72 ± 0.09; protein 0.34 ± 0.13 vs 0.85 ± 0.20) and rectus muscle (mRNA 0.83 ± 0.11 vs 1.28 ± 0.19; protein 0.78 ± 0.24 vs 1.23 ± 0.39). However, there were no significant differences between GDM women and controls with respect to the expression levels of FGF21 and β-klotho in the placenta and rectus muscle. There were almost no detectable FGF19 and FGF21 expressions in subcutaneous fat tissue. Furthermore, β-klotho expression levels were not different between the GDM and control group in subcutaneous fat.
conclusionsFGF19 expressions are decreased in the placenta and rectus muscle of women with GDM. This might contribute to the pathophysiology or development of GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.